Alumis’s genomic research guided its development of envudeucitinib, a TYK2 inhibitor that some analysts now view as best in class. The Phase 3 results that will support a planned FDA submission in plaque psoriasis are scheduled for presentation this weekend during the American Academy of Dermatology annual meeting in Denver.
Sanofi is building on its immunology ambitions by acquiring an early clinical Dren Bio drug candidate that offers a potential first-in-class approach to autoimmune disorders such as lupus. It’s the latest acquisition in what has become an active space for dealmaking.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Lupus is the lead autoimmune indication for Artiva Biotherapeutics, which has an early-stage clinical trial underway. Artiva’s allogeneic cell therapies are based on natural killer cells.
Autolus will apply the capital to its CAR T-cell therapy currently under FDA review in cancer and in early clinical development in lupus. Meanwhile, BioNTech will gain access to Autolus’s cell therapy manufacturing assets as well as technologies that could support the R&D of in vivo therapies and antibody drug conjugates.
Gilead Sciences is building up its autoimmune disease drug pipeline by turning to EVOQ Therapeutics, a startup with technology that takes a novel approach to restoring immune tolerance. For EVOQ, the Gilead deal is its second with a big pharma company.
An AstraZeneca lupus drug has been awarded FDA approval for treating the most common form of the autoimmune disorder. The regulatory decision gives AstraZeneca a product that can compete head-to-head with GlaxoSmithKline’s lupus drug, Benlysta.
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
During a panel discussion at the Connected Health Conference in Boston, two physicians and a patient touched on how virtual reality is aiding a variety of healthcare consumers. Yet as one panelist noted, we shouldn't overpromise what it can do.
Aurinia Pharmaceuticals put cashflow issues behind it on Tuesday, announcing a public offering that it expects will generate $150.5 million in gross proceeds for its Phase 3 trial in lupus nephritis. But not everyone was happy with the news.
Aurinia Pharmaceuticals took an existing drug and made just one amino acid modification. Is it another meaningless iteration, or could this drug really deliver major gains in lupus nephritis?
Aurinia was the subject of acquisition rumors in October. Two months later, it's flying solo with $25 million in new financing to power its Phase 3 trial for lupus nephritis.
Albuquerque, N.M.-based Exagen Diagnostics has raised $25 million in debt financing with a strategic investment from Capital Royalty Partners. The healthcare startup focuses on molecular testing innovations in rheumatology diagnostics, including rheumatoid arthritis and lupus, with its Avise line. Sales success attracted the investor. “The company has shown tremendous sales success with their lead product, […]
The approval of Human Genome Sciences/GlaxoSmithKline’s Benlysta last year ended a drought of new drug approvals for the autoimmune disease lupus that had lasted more than half a century. A lengthy pipeline of drugs is hoping to follow suit, including a preclinical biologic compound from a University of Washington spinoff that is hoping to progress […]
The experimental lupus treatment being developed by Argos Therapeutics is showing promise in early stage clinical trials, but the questions remain whether it’s enough progress to attract interest from a potential pharmaceutical partner. Argos released positive phase 1 clinical trial results for AGS-009 at the 2012 European League Against Rheumatism Congress (EULAR) in Berlin, […]
LabCorp (NYSE:LH) is partnering with molecular diagnostics firm XDx to develop a new diagnostic for lupus flares. Burlington, North Carolina-based LabCorp will work with XDx to develop a biomarker and commercialize a test for the flares — extended periods of activity for the autoimmune disease. Lupus causes the body’s immune system to attack its own […]